

Accepted Manuscript

Title: Up-regulation of Glutamate Transporter 1 (GLT-1) by Treatment with Clavulanic acid Attenuates Allodynia and Hyperalgesia in Neuropathic Rats

Authors: Bahareh Amin^a, Mahmoud Avaznia^b, Reihaneh Noorani^b, Soghra Mehri^c and Hossein Hosseinzadeh^c

^aCellular and Molecular Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, I.R. Iran.

^bPharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.

^cDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, I.R. Iran.

Correspondence: Prof Dr. Hossein Hosseinzadeh, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, I.R. Iran, Tel.: +985138819042, Fax: +985138823251, E-mail: hosseinzadehh@mums.ac.ir

Running title:

Clavulanic prevents neuropathic pain by GLT 1 upregulation

The number of text pages of the whole manuscript: 16

The number of figures: 2

To appear in: Basic and Clinical Neuroscience

Received date: 2016/03/27

Revised date: 2018/04/28

Accepted date: 2018/06/26

This is a “Just Accepted” manuscript, which has been examined by the peer-review process and has been accepted for publication. A “Just Accepted” manuscript is published online shortly after its acceptance, which is prior to technical editing and formatting and author proofing. Basic and Clinical Neuroscience Journal provides “Just Accepted” as an optional and free service which allows authors to make their results available to the research community as soon as possible after acceptance. After a manuscript has been technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Please note that technical editing may introduce minor changes to the manuscript text and/or graphics which may affect the content, and all legal disclaimers that apply to the journal pertain.

Please cite this article as:

Authors Amin, B. Avaznia, A. Noorani, R. Mehri , S. Hosseinzadeh H. (In Press). Up-regulation of Glutamate Transporter 1 (GLT-1) by Treatment with Clavulanic acid Attenuates Allodynia and Hyperalgesia in Neuropathic Rats. *Basic and Clinical Neuroscience*. Just Accepted publication Jun. 26, 2018. doi: <http://dx.doi.org/10.32598/bcn.9.10.110>
DOI: 10.32598/bcn.9.10.110

Abstract

Clavulanic acid (CLAV) is structurally similar to ceftriaxone, a potent stimulator of glial glutamate transporter-1 (GLT-1) expression. The present study aims at exploring the anti-nociceptive effects of CLAV, a beta-lactamase inhibitor in rats underwent sciatic nerve chronic constriction injury (CCI). CLAV (12.5, 25, 50 mg/kg) was administered intraperitoneally after the surgery for 14 consecutive days. Behavioral pain parameters were evaluated before and 3, 5, 7, 10 and 14 days after injury. Spinal GLT-1 level was measured via western blotting at days 7 and 14. CCI led to mechanical allodynia, cold allodynia and thermal hyperalgesia which started on postoperative days 3 and continued until the end of study. We found that CLAV (12.5 and 25 mg/kg) significantly attenuated all pain related behaviors as compared to the CCI animals treated with normal saline. Protein level of GLT-1 was down-regulated on day 14 following CCI and this phenomenon was reversed by fourteen days treatment of CLAV at the low doses of 12.5 and 25 mg/kg. These results suggest that CLAV might provide a new therapeutic strategy for neuropathic pain and its effect might be partially associated with the up-regulation of GLT-1.

Keywords: Clavulanic acid, Chronic constriction injury, Glutamate transporter 1

Introduction

Nerve injury-induced neuropathic pain is characterized by spontaneous pain, allodynia (when normally innocuous stimuli become painful) and hyperalgesia (when sensitivity to painful stimuli are increased). A variety of undesirable side effects of prototypical drugs makes this disease

remain a significant challenge in clinical practice (Dworkin et al., 2010). Therefore, discovering and developing new drugs provide a new way to treat refractory neuropathic pain.

Spinal cord glutamate has been reported to play a critical role in the development of hyperalgesia following nerve injury, by activating various glutamate receptors (Coderre et al., 2007; Zhang et al., 2009). Additionally, there is a link between glutamate transporters down-regulation and chronic pain conditions (Tao et al., 2005). Beta-lactam antibiotics enhance cellular glutamate uptake via spinal up-regulation of glutamate transporter subtype 1 (GLT-1). GLT1 is the predominantly astrocytic transporter, responsible for about 90% of glutamate uptake in the brain (Hu et al., 2010; Ramos et al., 2010).

The representative β -lactam antibiotic, ceftriaxone, has shown neuroprotective effects in some neurodegenerative diseases such as amyotrophic lateral sclerosis, multiple sclerosis, stroke, depression, tolerance, addiction, as well as neuropathic pain (Amin et al., 2012; Chen et al., 2012; Rothstein et al., 2005).

However, ceftriaxone has little therapeutic value due to concerns about resistance development to antibiotic (Kaplan and Mason, 1998). Another limitation of ceftriaxone is poor brain penetrability due to water-solubility of this compound that requires the administration of high doses of ceftriaxone leading to increased risk of adverse effects.

Ceftriaxone also needs parenteral administration, which is a painful and costly route diminishing patient compliance (Friedland et al., 1996).

Clavulanic acid (CLAV) is a member of the beta lactam antibiotics including penicillins and cephalosporins. However, this drug has weak antibacterial activities and consequently no therapeutic efficacy. CLAV acts as an irreversible inhibitor of bacterial beta-lactamase enzymes

that naturally degrade and inactive beta-lactam antibiotics. Due to this effect, CLAV has been commonly used in combination with some beta-lactam antibiotics such as ticarcillin and amoxicillin to overcome β -lactamase-mediated resistance (Crosby and Gump, 1982). CLAV readily penetrates to the blood-brain barrier (Nakagawa et al., 1994). This drug is orally stable and effective, with the bioavailability of approximately 64 to 75% (Bolton et al., 1986).

It has been reported that CLAV has neuroprotective effects to prevent or reduce neuronal damage in patients suffering from or susceptible to disease conditions characterized by loss of neuronal cells or loss of neuronal cell function (Slusher et al., 2000). CLAV has been shown anti-convulsant (Chen et al., 2013), antidepressant, anxiolytic effects (Kim et al., 2009) and stimulatory effect on sexual behaviors (Chan et al., 2009). Add to these, protection against neurodegenerative Parkinson's (PD) and Alzheimer's diseases (AD) (Huh et al., 2010), as well as attenuation of morphine's tolerance, rewarding, hyperthermic, and locomotor-sensitizing actions (Schroeder et al., 2014). Anti-nociceptive and anti-inflammatory effects of acute administration of CLAV have been demonstrated in acetic acid-induced writhing, formalin-induced pain as well as carrageenan-induced paw edema (Banani et al., 2012; Hajhashemi, 2014). However, the effect of this drug and possible mechanisms of action have not yet been evaluated in the chronic conditions of pain such as peripheral neuropathic pain. The present study was undertaken to evaluate antinociceptive effects of repeated administration of CLAV, intraperitoneally, in the chronic constriction injury (CCI) model of neuropathic pain in rats. Considering that neuropathic pain is associated with the decreased expression of glutamate transporters, drugs that increase the levels of these protein are effective in the treatment of neuropathic pain syndrome (Mao and Yang, 2010; Ramos et al., 2010). In this study, we wanted

to find out if beta-lactamase inhibitor, CLAV displays antinociceptive effects through glutamate transporter 1 (GLT1) activation or not. The protein levels of GLT-1 were evaluated via western blotting on days 7 and 14 after surgery in CCI animals treated with normal saline or CLAV.

Material and methods

Materials

CLAV was a gift from Daana Pharmaceutical Co. (Tabriz, Iran). It was dissolved in normal saline (NS). The solution was administered intraperitoneally (i.p.) at the doses of 12.5, 25 and 50 mg/kg. Doses of CLAV in the present study were comparable to the doses reported in the literature (Banani et al., 2012). Sodium pentobarbital was purchased from Claris Lifescience CO. (India), dissolved in NS and injected at a dose of 100 mg/kg/i.p.

Animals

Male Wistar rats, weighing 250 to 270 g at the start of surgery, were obtained from the animal center of School of Pharmacy, Mashhad University of Medical Sciences, Iran. Animals were maintained on a 12-h dark–light cycle at 22°C with food and water *ad libitum*. Behavioral studies were carried out in a quiet room between the hours of 9:00 AM and 11:00 AM. Animals in the present study were cared for and used in accordance with the principles and guidelines outlined by Internationally Accepted Principles for Laboratory Animal Use and Care, to minimize pain or discomfort in animals (Zimmermann, 1983). All experimental protocols were approved by the Mashhad University of Medical Sciences, Mashhad, Iran (approval number: 910634).

Chronic constriction injury

Mononeuropathy was induced as describe previously by the method of Bennet and Xie (Bennett et al., 2003). Rats were anaesthetized with sodium pentobarbital (60 mg/kg, i.p.). The sciatic

nerve was exposed at mid-thigh and freed of connective tissue. Then, four chromic gut sutures (4–0) were loosely tied around the nerve with a 1.0–1.5 mm interval between each of them. The wound was closed in layers with silk sutures (4–0).

Experimental protocol

Animals were divided into the following groups:

Group I: Naïve animals (n=6).

Group II: Sham group: Rats exposed to similar surgical conditions except for nerve ligation and treated with the high dose of clavulanic acid (50 mg/kg) (n=9).

Group III: Rats subjected to CCI, were injected with normal saline once daily for fourteen days, which began immediately after injury and were designated to be the control group (n=9).

Groups IV, V and VI: CCI + i.p. CLAV (12.5, 25 and 50 mg/kg) rats, respectively, once daily for fourteen days, which began immediately after injury (n=9).

Behavioral testing were performed in all animals 1 day before the operation (day -1), and subsequently on days 3, 5, 7, 10 and 14th after the sciatic nerve chronic constriction injury.

To determine time course of spinal GLT1s changes after CCI, on postoperative day 7, or 14 after the end of behavioral tests, three separate animals in each group were harvested and lumbar spinal cord sections were dissected. The samples were kept in the individual tubes, quickly frozen in liquid nitrogen and then stored at –80 °C until they were used.

Nociceptive behavior tests

Measurement of mechanical allodynia

Mechanical allodynia was measured by the calibrated von Frey filaments (Stoelting, Wood Dale, IL, USA). Rats were placed in individual transparent Perspex cubicles with a wire mesh bottom,

to be familiar with the environment. The filaments of sequentially increasing stiffness were applied to the plantar surface of hind paw of animals. The force needed to elicit animal withdrawal was expressed as the mechanical paw threshold (PWT) in grams (g) (Bennett et al., 2003).

Measurement of cold allodynia

Fifteen minutes after the end of mechanical allodynia test, acetone drop was used to the plantar surface of the injured hind paw to assess cold allodynia. Acetone was applied five times to the hind paw, with a gap of 5 min between the applications and a sudden withdrawal response to the acetone was considered as a sign of cold allodynia. The frequency of paw withdrawal was expressed as a percentage (the number of paw withdrawals divided by the total number of trials, times 100) (Yoon et al., 1994).

Measurement of thermal hyperalgesia

Thermal hyperalgesia was assessed using a Plantar Test Apparatus (Ugo Basile, Varese, Italy). The animals were acclimatized in the plastic cage of apparatus for about 30 min. The plantar surface of the hind paw was exposed to a beam of radiant heat through the glass floor. Three latency measurements were taken and averaged for each hind paw for each session of testing. The cut-off time was 30 sec in order to prevent tissue damage (Hargreaves et al., 1988).

Western blot

At respective time points (day 7 and 14 post-CCI) spinal cord samples of sham, NS-CCI animals and CCI animals treated with CLAV at different doses of 25, 50 and 100 were homogenized in the lysis buffer (50 mM Tris-HCl (pH: 7.4), 2 mM EDTA, 2 mM EGTA, 10 mM NaF, 1 mM sodium orthovanadate (Na_3VO_4), 10 mM β -glycerophosphate, 0.2% W/V sodium deoxycholate, 1 mM

phenylmethylsulfonyl fluoride (PMSF), and complete protease inhibitor cocktail (Roche, Mannheim, Germany). The homogenate was then sonicated on ice with three bursts at high intensity lasted 10-sec, with a 10-sec cooling period between each burst. At the end homogenized tissues were centrifuged at 10,000g for 10 min at 4°C and proteins were quantified using the Bradford assay kit (BioRad) and adjusted (Bradford, 1976). Samples were electrophoresed through SDS-polyacrylamide gels and transferred to PVDF membranes. Non-fat milk in TBS (5%) was used to block blots for 1 h prior to incubation with antibodies. Primary antibodies utilized in this study, were as follows: Rabbit monoclonal anti-serum against GLT-1 (Cell Signaling#3838) and Rabbit polyclonal anti-serum against β -actin (Cell Signaling#4967). After washing three times with TBST, blots were probed with HRP-conjugated antibodies (Cell Signaling#7074) and developed with enhanced chemiluminescence (ECL, USA) reagents. Alliance 4.7 Gel doc (UK) was used to visualize the peroxidase-coated bands. Bands of proteins were densitometrically quantified using UVtec software (UK).

Data analysis and statistics

The results were showed as the mean \pm SEM. Repeated-measures analysis of variance (ANOVA) tests for behavioral studies were done with group (between-subjects factor) and time after nerve ligation (within-subjects factor). The Bonferroni's test was examined post hoc for multiple comparisons at individual time points between groups. Data from western blot test were analyzed by using one-way ANOVA followed by Tukey's test. For all tests $P < 0.05$ was considered statistically significant.

Results

Per se administration of CLAV (50 mg/kg i.p.) to sham animals did not change behavioral parameters as compared to naïve ones (data not shown).

The influence of clavulanic acid on the CCI-induced development of mechanical allodynia

Before surgery (day -1), there was no significant difference in the paw withdrawal threshold to tactile stimuli (mechanical allodynia) in CCI group (52 ± 5.3 g) as compared with sham animals (48.6 ± 5.6 g). Decreased response threshold to the mechanical allodynia developed 3 days after loose ligation of sciatic nerve as compared to sham animals (5.3 ± 0.75 g and 48.5 ± 5.7 respectively; $P < 0.001$) (Fig. 1A). The high dose of 50 mg/kg of CLAV failed to attenuate hypersensitivity to von Frey filaments at all days of study. Administration of CLAV (12.5 and 25 mg/kg) attenuated CCI-induced decrease in the paw withdrawal threshold on postoperative days 3, 5, 7, 10 and 14 as compared to normal saline treated group. Fig. 1A shows time course of increase in the paw withdrawal threshold produced by CLAV in CCI animals.

The influence of clavulanic acid on the CCI-induced development of cold allodynia

There was no significant difference in the paw withdrawal frequency to acetone drop (cold allodynia) in CCI animals (6.7 ± 7.3 %) as compared with sham-operated group (8.8 ± 3.5 %), before surgery (day -1). Rats receiving constriction of the left sciatic nerve developed robust cold allodynia as early as day 3 post-CCI (73 ± 7.4 %) that lasted throughout the study. In contrast, the threshold for the sham animals was unchanged (20 ± 5.7 %) ($P < 0.001$, Fig. 1B). Intraperitoneal treatment with CLAV (12.5, 25 mg/kg) but not the high dose of 50 mg/kg for 14 days reversed nerve injury-induced cold allodynia on days 3, 5, 7, 10 and 14. Fig. 1B shows time course of decrease in the paw withdrawal frequency produced by CLAV in CCI animals.

The influence of clavulanic acid on the CCI-induced development of thermal hyperalgesia

Before surgery, the mean paw withdrawal latency in CCI rats (27.2 ± 1.3 sec) did not significantly differ as compared with sham animals (28 ± 1.5 sec). Five days after surgery, the neuropathy induced by CCI resulted in a significant development of thermal hyperalgesia (9.4 ± 1.8) as compared to the sham control group (24 ± 1.4) ($P < 0.001$) which continued on postoperative days 7, 10 and 14 in normal saline-treated CCI rats (Fig. 1C). Rats were concomitantly administered with CLAV (12.5 and 25 mg/kg) for 14 days significantly attenuated such decreased mean paw withdrawal latency as compared with NS-CCI animals. CLAV at the dose of 50 mg/kg attenuated hypersensitivity to thermal stimulus but was not able to retain such effect until the end of study. Fig. 1C shows time course of increase in the paw withdrawal latency produced by CLAV.

The influence of clavulanic acid on the CCI-induced changes in GLT1

The results of western blot analysis are shown in Fig. 2A and B. When compared with sham rats, the protein levels of GLT1 decreased on day 7, but not to a significant extent (data not shown). A significant increase was detected in the lumbar spinal cord levels of GLT1 protein in CCI rats, on day 14 ($P < 0.01$). CLAV at the low doses of 12.5 mg/kg ($P < 0.01$) and 25 mg/kg ($P < 0.05$) increased the GLT1 levels of spinal cord in CCI animals.

Discussion

CCI of sciatic nerve induced mechanical allodynia and cold allodynia, which started from the postoperative day 3 and lasted up to day 14. Fourteen-day administration of CLAV (12.5 and 25, i.p), but not 50 mg/kg, beginning immediately after the injury was able to attenuate mechanical allodynia and cold allodynia developed in CCI animals in relation to NS-CCI animals. Thermal hyperalgesia started with a latency on day 5 after CCI. CLAV at three applied doses decreased

hyperalgesia to thermal radiant heat stimulus; however, the effect of 50 mg/kg of CLAV was not remained until day 14.

In a study by kim et al., (2009) low dose, seven days administration of CLAV showed greater anxiolytic effect. An inverted-U shaped dose response might be responsible for such profile of CLAV's dose-response, which is called hormetic response (Calabrese and Baldwin, 2001).

We hypothesized here that CLAV a structurally related β -lactamase inhibitor will also influence the GLT1 expression. To this end, we assessed the effects of repeated CLAV administration on the protein levels of GLT1 on days 7 and 14 post-CCI.

Based on our results, GLT1 protein content decreased in CCI animals treated with normal saline on postoperative day 7 but not to a significant degree, as compared to sham group. However, on day 14, levels of protein significantly decreased in the NS-CCI spinal cord of animals. In a study conducted on Sprague Dawley CCI rats, Sung et al, found a biphasic change in the GLT-1 level after CCI; GLT1 was up-regulated on days 3 and 4, followed by a decrease on postoperative days 7 and 14 (Sung et al., 2003). The observed discrepancies might be attributed to species difference and methods used. The level of GLT1 was elevated on day 14 after intraperitoneal administration of CLAV at the low doses of 12.5 and 25 but not the high dose (50 mg/kg) in the lumbar spinal cord of CCI rats. Considering that hyperalgesia was attenuated by CLAV 50 mg/kg, it might be postulated that other pathways have more important role in the induction of thermal hyperalgesia. Although, time course of GLT-1 upregulation by clavulanic acid was not investigated on days 1 and 3 after CCI, but will be the focus of future.

Our data on the upregulation of GLT-1 are supported by Rawls et al., (2010) results reporting that GLT-1 transporter inhibitor dihydrokainite (DHK) augmented seizure-like activity induced by

glutamate and cocaine. In the study of Schroeder et al., (2014) CLAV (10 mg/kg) showed reduction in rewarding and sensitizing effects of morphine, similar to ceftriaxone at the dose 200 mg/kg.

Neuroprotective effects of beta lactams antibiotics is principally dependent on the GLT1 up-regulation and is perhaps concentrated on the beta-lactam ring itself (Konaklieva et al., 2009). Ceftriaxone, clavulanic acid, and tazobactam prevented the seizure-like activity induced by glutamate or cocaine administration in planarian, whereas vancomycin, an antibiotic does not have the beta-lactam ring, was not active in this assay. In the screening study of Rothstein et al., (2005) non-b-lactam antibiotics including kanamycin, fluconazole, minocycline, polymyxin and doxycycline had no effect on GLT1 protein expression.

Another reason supporting GLT-1 may have a role in the antinociceptive effects of clavulanic acid, is that acute administration of this drug failed to show anti-seizure activity in three models of seizure including 6-Hz seizure threshold, maximal electroshock seizure threshold (MEST) test, and intravenous pentylenetetrazole (i.v. PTZ) seizure. Sexual stimulating activity observed with the acute administration of high dose of clavulanic acid was less than that obtained with the low dose in chronic administration (Rawls et al., 2010). In accordance with this, seven-day administration of ceftriaxone is required for ceftriaxone to increase the protein levels of GLT-1 in brain of rats (Rothstein et al., 2005). However, contribution of other pathways in antinociceptive effects of CLAV is also possible.

Supra-spinal dopaminergic system is also related to the suppression of tonic pain. In a study by Coffeen et al. (2010), inflammation induced by carrageenan decreased extracellular levels of dopamine in the cortex of rats, correlated with the decreased paw withdrawal latency in plantar

test. Furthermore, L-Dopa decreased pain in diabetic polyneuropathy patients (Ertas et al., 1998). Clavulanic acid treatment protected hippocampal and dopamine neurons in kainic acid and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rodent models displaying the characteristics of idiopathic AD and PD respectively, with improving the MPTP-induced motor deficits. Sanna et al., (2011) reported that clavulanic acid induced penile erection and yawning in male rats by increasing the serotonin and dopamine neurotransmission. In an *in vitro* study conducted on the PC12 and SH-SY5Y cells, clavulanic acid enhanced release of dopamine in PC12 and SH-SY5Y cells without affecting dopamine synthesis (Kost et al., 2011).

In addition, development of neuropathic pain may be associated with the activation of apoptotic events (Siniscalco et al., 2007). Bax as an apoptotic factor, and Bcl2 an anti-apoptotic protein in the Bcl2 family are responsible for the subsequent activation of caspases and mitochondrial-mediated apoptosis (Keane et al., 2001). Kost et al., (2012) investigated the anti-apoptotic property of clavulanic acid. A significant increase in the mitochondrial membrane potential of cells treated with clavulanic acid was observed in cells incubated with neurotoxin 1-methyl-4-phenylpyridinium (MPP+), as a model of Parkinson's disease. Increased levels of Bax and cytochrome C, as well as caspases 3 and 9 activation induced by MPP+ were decreased in clavulanic acid treated cells. Anti-apoptotic Bcl-xl protein was also normalized. However, it is not the only mechanism and CLAV may act through multiple mechanisms of action.

Conclusion

In summary our data shows that CLAV displays anti-allodynic and anti-hyperalgesic effects in sciatic nerve CCI rats. Increased protein levels of GLT-1 contribute, at least in part, to the antinociceptive effects obtained with this drug. The property that clavulanic acid possesses little

intrinsic anti-bacterial activities strengthens its application for further therapeutic development. Structural similarities between CLAV and ceftriaxone, and the more favorable pharmacokinetic of CLAV suggest that this drug has the ability for further studying the management of chronic pain conditions.

Acknowledgments

The authors are thankful to the Vice Chancellor of Research, Mashhad University of Medical Sciences for their financial support. The results presented here are part of Dr. Avaznia thesis towards getting Pharm. D degree.

Conflict of Interest

The authors declare no conflict of interest.

References

- Amin, B., Hajhashemi, V., Hosseinzadeh, H., Abnous, K. (2012). Antinociceptive evaluation of ceftriaxone and minocycline alone and in combination in a neuropathic pain model in rat. *Neuroscience*. 224, 15-25.
- Banani, A., Maleki-Dizaji, N., Garjani, A., Soraya, H., Mostafalou, S., Ziaee, M. (2012). Clavulanic acid exhibits anti-inflammatory effects on carrageenan-induced paw edema model of inflammation in rats. *Annals of Biological Research*. 3, 3312-3320.
- Bennett, G.J., Chung, J.M., Honore, M., Seltzer, Z. (2003). Models of neuropathic pain in the rat. *Currents Protocols in Pharmacology*. Chapter 5, Unit 9.14.
- Bolton, G.C., Allen, G.D., Davies, B.E., Filer, C.W., Jeffery, D.J. (1986). The disposition of clavulanic acid in man. *Xenobiotica*. 16, 853-863.
- Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*. 72, 248-254.
- Calabrese, E.J., Baldwin, L.A. (2001). The frequency of U-shaped dose responses in the toxicological literature. *Toxicological Sciences*. 62, 330-338.
- Chan, J.S., Kim, D.J., Ahn, C.H., Oosting, R.S., Olivier, B. (2009). Clavulanic acid stimulates sexual behaviour in male rats. *European Journal of Pharmacology*. 609, 69-73.
- Chen, J., Shang, X., Hu, F., Lao, X., Gao, X., Zheng, H., Yao, W. (2013). beta-Lactamase inhibitors: an update. *Mini Reviews in Medicinal Chemistry*. 13, 1846-1861.
- Chen, Z., He, Y., Wang, Z.J. (2012). The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia in mice. *Neuroscience Letters*. 509, 69-71.

- Coderre, T.J., Kumar, N., Lefebvre, C.D., Yu, J.S. (2007). A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. *Journal of Neurochemistry*. 100, 1289-1299.
- Coffeen, U., Ortega-Legaspi, J.M., de Gortari, P., Simón-Arceo, K., Jaimes, O., Amaya, M.I., et al. (2010). Inflammatory nociception diminishes dopamine release and increases dopamine D2 receptor mRNA in the rat's insular cortex. *Molecular Pain*. 6, 75.
- Crosby, M.A., Gump, D.W. (1982). Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against *Bacteroides* spp. correlated with beta-lactamase production. *Antimicrobial Agents and Chemotherapy*. 22, 398-405.
- Dworkin, R.H., O'Connor, A.B., Audette J.R., Baron, G.K., Gourlay, M.L., Haanpää, J.L., et al. (2010). Recommendations for the pharmacological management of neuropathic pain: an overview and literature update, *Mayo Clinic Proceedings*. 85, S3-14.
- Ertas, M., Sagduyu, A., Arac, N., Uludag, B., Ertekin, C. (1998). Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. *Pain*. 75, 257-259.
- Friedland, L.R., Kulick, R.M., Biro, F.M., Patterson, A. (1996). Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis. *Annals of Emergency Medicine*. 27, 299-304.
- Hajhashemi, V., Dehdashti, K.H. (2014). Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models. *Research in Pharmaceutical Sciences*. 9, 315-321.
- Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J. (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain*. 32, 77-88.
- Hu, Y., Li, W., Lu, L., Cai, J., Xian, X., Zhang, M., et al. (2010). An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats. *Pain*. 148, 284-301.
- Huh, Y., Ju, M.S., Park, H., Han, S., Bang, Y.-M., Ferris, C.F., et al. (2010). Clavulanic acid protects neurons in pharmacological models of neurodegenerative diseases. *Drug Development Research*. 71, 351-357.
- Kaplan, S.L., Mason, E.O., Jr. (1998). Management of infections due to antibiotic-resistant *Streptococcus pneumoniae*. *Clinical Microbiology Reviews*. 11, 628-644.
- Keane, R.W., Kraydieh, S., Lotocki, G., Bethea, J.R., Krajewski, S., Reed, J.C., et al. (2001). Apoptotic and anti-apoptotic mechanisms following spinal cord injury. *Journal of Neuropathology & Experimental Neurology*. 60, 422-429.
- Kim, D.J., King, J.A., Zuccarelli, L., Ferris, C.F., Koppel, G.A., Snowdon, C.T., et al. (2009). Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. *Pharmacology Biochemistry and Behaviour*. 93, 112-120.
- Konaklieva, M.I., Plotkin, B.J., Herbert, T. (2009). β -Lactams as neuroprotective agents. *Anti-Infective Agents in Medicinal Chemistry*. 8, 28-35.
- Kost, G.C., Selvaraj, S., Lee, Y.B., Kim, D.J., Ahn, C.H., Singh, B.B. (2011). Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. *Neuroscience Letters*. 504, 170-175.
- Kost, G.C., Selvaraj, S., Lee, Y.B., Kim, D.J., Ahn, C.H., Singh, B.B. (2012). Clavulanic acid inhibits MPP(+)-induced ROS generation and subsequent loss of dopaminergic cells. *Brain Research*. 1469, 129-135.
- Mao, Q.X., Yang, T.D. (2010). Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. *Brain Research Bulletin*. 81, 424-427.
- Nakagawa, H., Yamada, M., Tokiyoshi, K., Miyawaki, Y., Kanayama, T. (1994). Penetration of potassium clavulanate/ticarillin sodium into cerebrospinal fluid in neurosurgical patients. *The Japanese Journal of Antibiotics*. 47, 93-101.

- Ramos, K.M., Lewis, M.T., Morgan, K.N., Crysdale, N.Y., Kroll, J.L., Taylor, F.R., et al. (2010). Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. *Neuroscience*. 169, 1888-1900.
- Rawls, S. M., Karaca, F., Madhani, I., Bhojani, V., Martinez, R. L., Abou, G., et al. (2010). Beta lactamase inhibitors display anti-seizure properties in an invertebrate assay. *Neuroscience*. 169, 1800-1804.
- Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., et al. (2005). Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. *Nature*. 433, 73-77.
- Sanna, F., Melis, M.R., Angioni, L., Argiolas, A. (2013). Clavulanic acid induces penile erection and yawning in male rats: comparison with apomorphine. *Pharmacology Biochemistry and Behaviour*. 103, 750-755.
- Schroeder, J.A., Tolman, N.G., McKenna, F.F., Watkins, K.L., Passeri, S.M., Hsu, A.H., et al. (2014). Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug? *Drug and Alcohol Dependence*. 142, 41-45.
- Siniscalco, D., Fuccio, C., Giordano, C., Ferraraccio, F., Palazzo, E., Luongo, L., et al. (2007). Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic pain. *Pharmacological Research*. 55, 158-166.
- Slusher, B.S.K., Jackson, Paul, F., Tays, K.L., Maclin, K.M. (2000). *Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors*. Vol., ed.eds. Guilford Pharmaceuticals Inc., United States.
- Sung, B., Lim, G., Mao, J. (2003). Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. *Journal of Neuroscience*. 23, 2899-2910.
- Tao, Y.-X., Gu, J., Stephens Jr, R.L. (2005). Role of spinal cord glutamate transporter during normal sensory transmission and pathological pain states. *Molecular Pain*. 1, 30.
- Yoon, C., Young Wook, Y., Heung Sik, N., Sun Ho, K., Jin Mo, C. (1994). Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. *Pain*. 59, 369-376.
- Zhang, H.M., Chen, S.R., Pan, H.L. (2009). Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain. *Neuroscience*. 158, 875-884.
- Zimmermann, M. (1983). Ethical guidelines for investigation of experimental pain in conscious animals. *Pain*. 16, 109-110.

Figure 1. Effects of clavulanic acid (CLAV) on the induction of A: mechanical allodynia, B: cold allodynia and C: thermal hyperalgesia after chronic constriction injury (CCI) to sciatic nerve. Treatment was performed with intraperitoneal injection of 12.5, 25 and 50 mg/kg of CLAV, once daily for 14 days beginning immediately after the operation. Values are mean±S.E.M., n=9 rats per group; Data were analyzed by two-way ANOVA with repeated measure, followed by

Bonferroni's post hoc test. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ as compared to CCI rats treated with normal saline (NS). ### $p < 0.001$ indicates comparison between CCI-NS and sham animals.

Figure 2. A: Effect of clavulanic acid (CLAV) on the spinal glutamate transporter 1 (GLT-1) protein level of CCI rats in western blotting analysis. CLAV was administered 12.5, 25, and 50 mg/kg, i.p., once daily for 14 days beginning immediately after the operation. Beta-actine is the loading control protein B: Represents quantitative presentation of the immunoblots. Values have been shown as the mean \pm SEM (n = 3). Data were analyzed by one-way ANOVA followed by Tukey's for pair wise comparison. * $p < 0.05$ and ** $p < 0.01$ as compared with CCI rats treated with normal saline). ## $p < 0.01$ comparison between CCI-NS and sham animals.